Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares By Investing.com

Atara Biotherapeutics () director Brian N. Cherry purchased 104,166 shares of the company’s common stock on September 4, 2026. The transaction was executed at a price of $9.6 per share, totaling approximately $999,993. The purchase comes as the stock trades at $9.76, reflecting an 81% surge over the past six months. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, with the company carrying a market capitalization of $95.66 million.

Following this acquisition, Mr. Cherry directly holds 166,486 shares of Atara Biotherapeutics common stock. The shares were purchased by Mr. Cherry from the Issuer, Atara Biotherapeutics, through its sales agent, TD Securities (USA) LLC, in accordance with a Sales Agreement dated November 1, 2023. InvestingPro subscribers have access to 5 additional exclusive tips about ATRA’s financial outlook and performance.

In other recent news, Atara Biotherapeutics has announced a change to its board of directors. Carol Gallagher, who served the company for 13 years in various capacities, is departing from the board. Brian Cherry has been appointed as a new director, as stated in a press release. Atara’s President and CEO, Cokey Nguyen, expressed appreciation for Gallagher’s dedication to the company and its shareholders. This change marks a significant development in the company’s governance as it continues to navigate its strategic goals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.